ARCHIVES

Herceptin Regimen Minus Adriamycin Increases Survival With Less Toxicity

This article is from The Cancer Letter archive.

Vol. 34 No. 10 | October 28, 2011

Download PDF Visit The Full Archive

Related Articles

FDA, ASCO Meet to Review Drug Approval Endpoints

April 25, 2003

Amgen Commits $1.5M To CDC Foundation For Education Program

May 29, 2009

FDA Needs Staff, Funds But first Must Determine Priorities, GAO Says

November 17, 1989

NIH, Myriad Talked About CRADA, Didn’t Agree, Varmus Writes

November 4, 1994

WETA Relents Will Air Documentary

April 10, 1987

Consensus Panel Say Surgery, Radiation Both Effective For Clinically Local Prostate Cancer

June 26, 1987